AN2 THERAPEUTICS INC (ANTX:NASDAQ)
$3.86 0.23 (6.3361%)
Analysed AN2 THERAPEUTICS INC (ANTX:NASDAQ) News Sources
GSK (LSE:GSK) Deepens Its Drug Pipeline Through Two Research Partnerships
08-10-2026
yahoo.com
AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease
04-06-2026
yahoo.com
AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights
11-08-2026
yahoo.com
AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer
24-08-2026
yahoo.com
AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)
16-09-2026
yahoo.com
AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK
28-09-2026
yahoo.com
GSK (LSE:GSK) The Latest Update Raises A Bigger Question
30-09-2026
yahoo.com
AN2 Therapeutics to Participate at Upcoming Investor Conferences
20-10-2026
yahoo.com
AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms
21-10-2026
yahoo.com
AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4)
23-10-2026
yahoo.com
What is the current price of AN2 THERAPEUTICS INC (ANTX:NASDAQ)?
The current price of AN2 THERAPEUTICS INC (ANTX:NASDAQ) is $3.86.
AN2 THERAPEUTICS INC (ANTX:NASDAQ) absolute price change since previous trading day?
The absolute price change of AN2 THERAPEUTICS INC (ANTX:NASDAQ) since the previous trading day is $0.23.
AN2 THERAPEUTICS INC (ANTX:NASDAQ) percentage price change since previous trading day?
The percentage price change of AN2 THERAPEUTICS INC (ANTX:NASDAQ) since the previous trading day is 6.3361%.
What is the most recent average sentiment score for AN2 THERAPEUTICS INC (ANTX:NASDAQ)?
The most recent average sentiment score for AN2 THERAPEUTICS INC (ANTX:NASDAQ) is 77 out of 100.
What is the most recent average sentiment for AN2 THERAPEUTICS INC (ANTX:NASDAQ)?
The most recent sentiment for AN2 THERAPEUTICS INC (ANTX:NASDAQ) is .
SEC-8K** Filing Available For AN2 THERAPEUTICS INC (ANTX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.